Publication:
Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
| datacite.subject.fos | oecd::Medical and Health sciences | |
| dc.contributor.author | The Hong Phong Nguyen | |
| dc.contributor.author | V. Bharath Kumar | |
| dc.contributor.author | Vinoth Kumar Ponnusamy | |
| dc.contributor.author | Thi Thu Thao Mai | |
| dc.contributor.author | Phuong Tran Nhat | |
| dc.contributor.author | Kathirvel Brindhadevi | |
| dc.contributor.author | Arivalagan Pugazhendhi | |
| dc.date.accessioned | 2022-11-09T11:03:07Z | |
| dc.date.available | 2022-11-09T11:03:07Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Over the past few decades, many of the phytochemicals have been shown to possess extraordinary anticancer effects, clinical tested, approved as drugs, and currently in use. A considerable number of phytochemicals either as a single-agent or combined with existing anticancer drugs at pre-clinical and clinical levels have been evaluated to date. However, the clinical trials on phytochemical evaluations against the world's top-ranked cancer, NSCLC, was found to be a very little. Some of the phytochemicals that showed significant anticancer activity against NSCLC in vitro and/or in vivo at the preclinical levels are highlighted in this review article. There are several impediments such as poor solubility, poor bioavailability, low stability, a requirement of high doses, safety and toxicity that limits the wide-spread use of phytochemicals in clinical oncology. Nanotherapeutic systems can help to overcome the aforementioned issues and wide open the gates to focus on phyto-oncotherapy, in particular NSCLC. The current review aims to summarize the importance of phytochemicals as anticancer agents, with a special mention on nano-formulations to treat non-small cell lung cancer (NSCLC). | |
| dc.identifier.doi | 10.1016/j.procbio.2021.02.004 | |
| dc.identifier.uri | http://repository.vlu.edu.vn:443/handle/123456789/1138 | |
| dc.language.iso | en_US | |
| dc.relation.ispartof | Process Biochemistry | |
| dc.relation.issn | 1359-5113 | |
| dc.subject | Phytoceuticals | |
| dc.subject | NSCLC | |
| dc.subject | Preclinical | |
| dc.subject | Clinical | |
| dc.subject | Nanoscale | |
| dc.subject | Cancer | |
| dc.title | Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy | |
| dc.type | journal-article | |
| dspace.entity.type | Publication | |
| oaire.citation.volume | 104 |